Long-term Outcomes and Quality of Life Following Laparoscopic One-anastomosis Gastric Bypass: Single-center Experience.

Authors

Anna Kirshtein, Boris Kirshtein, Yehuda Hershkovitz, Oded Zmora, Hasan Kais

Published in

Surgical laparoscopy, endoscopy & percutaneous techniques. Sep 10, 2026. Epub Sep 10, 2026.

Abstract

Laparoscopic one-anastomosis gastric bypass (OAGB) has become one of the leading bariatric procedures for severe obesity in Israel over the past 8 years. While short-term outcomes have been widely reported in the literature, long-term data remain limited. This study summarizes 7-year outcomes and quality of life (QoL) following OAGB.
A retrospective review was conducted of consecutive patients who underwent OAGB between January and December 2016 at Shamir Medical Center. Data were collected from a prospective bariatric database and analyzed retrospectively. All patients participated in a structured phone interview in late 2024, with a mean follow-up period of 7 years. Surgical outcomes were evaluated based on pre- and postoperative comorbidities, early and late complications, weight loss, patient satisfaction, and QoL using the Bariatric Analysis and Reporting Outcome System (BAROS) II.
Eighty patients were included in the final analysis: 55 females (68.8%) and 25 males (31.2%), with a mean age of 44.3 years (range: 20-68). The mean preoperative weight was 103.2 kg, and the mean BMI was 40.9 kg/m². The mean operative time was 101.9 minutes, and the average hospital stay was 3.3 days. Major complications within 30 days occurred in 5.1% of cases. The mean BMI decreased to 28.1 kg/m² at 1.7 years and remained stable throughout the follow-up period. Mean %EWL was 80.2% at 6 months and 74.6% at 7 years postoperatively. Resolution of type 2 diabetes, hypertension, obstructive sleep apnea, and hyperlipidemia was observed in over 80% of patients with preoperative comorbidities. QoL improved over the 7-year follow-up.
OAGB is a technically straightforward and safe procedure with short operative and hospitalization times. It provides sustained weight loss, high resolution of comorbidities, and long-term improvement in quality of life.

PMID:
42721067
Bibliographic data and abstract were imported from PubMed on 11 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.